Rocuronium has the most rapid onset of action among the nondepolarizing neuromuscular blocking drugs; doses of 0.6-0.9 mg/ Kg guarantee a complete block in about 60-90 seconds and good or excellent intubating conditions in 60 seconds [1,2].
Its pharmacokinetics and pharmacodynamics can be influenced by different factors as age, inhaled anesthetics, hepatic and renal insufficiency, hypothermia, gender and obesity [3-8].
Rocuronium has been shown to cause less histamine release and cardiovascular instability than benzylisoquinolinum neuromuscular blocking agents such as atracurium and mivacurium , however it can act as an antigen: in our clinical experience three acute reactions occurred after its administration in the same patient.
Published on: Sep 6, 2014 Pages: 13-15
Catholic University of Rome, Italy
Peertechz Journal of Orthopedics and Rheumatology
Leeds Beckett University, UK
Archives of Community Medicine and Public Health
University of Athens, Greece
Journal of Novel Physiotherapy and Physical Rehabilitation
Journal of Addiction Medicine and Therapeutic Science
Democritus University of Thrace , Greece
International Journal of Vascular Surgery and Medicine